Loading... Please wait...
App Store Download on the App Store Google Play GET IT ON Google Play

ProQR Therapeutics N.V. (PRQR) Stock Price, News & Analysis

Currency in USD Disclaimer
Add to Alerts
Add to Watchlist
$1.70 $0.06 (3.66%)
$1.63
$1.72
$1.11
$3.29
Track all markets on TradingView

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -3.83
  • Piotroski Score 2.00
  • Grade Buy

Company brief: ProQR Therapeutics N.V. (PRQR)

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Price Target and Rating

  • $3.75
  • $5.00
  • $2.00
  • N/A
  • Neutral
  • N/A
  • N/A

Profitability

  • -$0.36
  • -5.14
  • -5.14
  • -5.14
  • $-27,542,618

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Latest News of PRQR

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Log In

or
Continue with Google Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Sign Up With Email Address
or
Continue with Google Continue with Apple

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.